What's new

Human medicines European public assessment report (EPAR): Zoely, nomegestrol,estradiol, Date of authorisation: 26/07/2011, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Zoely, nomegestrol,est...

Human medicines European public assessment report (EPAR): Vevizye, ciclosporin, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Vevizye, ciclosporin, ...

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Prevenar 20 (previousl...

EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 March 2025, 14:00 (CET) to 5 March 2025, 18:00 (CET)

EMA workshop on the challenges in drug development, reg...

Feb 19, 2025 0

EMA workshop on the challenges in drug development, regulation and clinical prac...

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pre...

Finding clinical trials with the ACT EU Trial Map, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 March 2025, 13:30 (CET) to 7 March 2025, 14:30 (CET)

Finding clinical trials with the ACT EU Trial Map, Onli...

Feb 19, 2025 0

Finding clinical trials with the ACT EU Trial Map, Online, European Medicines Ag...

Human medicines European public assessment report (EPAR): Balversa, Erdafitinib, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Balversa, Erdafitinib,...

Human medicines European public assessment report (EPAR): Apretude, cabotegravir, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Apretude, cabotegravir...

Human medicines European public assessment report (EPAR): Thyrogen, thyrotropin alfa, Date of authorisation: 09/03/2000, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Thyrogen, thyrotropin ...

Clinical Trial Information System (CTIS) - Sponsor hand...

Feb 19, 2025 0

Clinical Trial Information System (CTIS) - Sponsor handbook

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Date of authorisation: 12/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab,...

Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10), Date of authorisation: 13/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacteri...

Assessment templates and guidance

Assessment templates and guidance

Feb 19, 2025 0

Assessment templates and guidance

Generic and hybrid applications

Generic and hybrid applications

Feb 19, 2025 0

Generic and hybrid applications

Biosimilar medicines: marketing authorisation

Biosimilar medicines: marketing authorisation

Feb 19, 2025 0

Biosimilar medicines: marketing authorisation

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Da...

Human medicines European public assessment report (EPAR): Blenrep, belantamab mafodotin, Date of authorisation: 25/08/2020, Revision: 8, Status: Withdrawn

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Blenrep, belantamab ma...

Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F Treatment of multiple myeloma, 16/10/2017 Withdrawn

Orphan designation: Humanised monoclonal antibody targe...

Feb 19, 2025 0

Orphan designation: Humanised monoclonal antibody targeting B-cell maturation an...

Human medicines European public assessment report (EPAR): Galvus, vildagliptin, Date of authorisation: 25/09/2007, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Galvus, vildagliptin, ...

Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Date of authorisation: 29/06/2004, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025 0

Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Da...

Type-IA variations: questions and answers

Type-IA variations: questions and answers

Feb 19, 2025 0

Type-IA variations: questions and answers

Human medicines European public assessment report (EPAR): Ravicti, glycerol phenylbutyrate, Date of authorisation: 26/11/2015, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Ravicti, glycerol phen...

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Da...

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel...

8
9
10
11
12

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.